glofitamab

An investigational, bivalent T-cell–engaging bispecific antibody

A T-cell–engaging bispecific antibody, glofitamab is designed to bind to CD3 on T cells and has a distinctive bivalent (2:1) structure that may enable high-avidity binding to CD20 on B cells1

CD=cluster of differentiation.